Objective: Feeding intolerance is a common problem in the neonatal intensive care unit (NICU) and some cases might be causally related to atrophic changes in the small bowel mucosa. We speculated that for such patients, feeding tolerance might improve after oral administration of enterocyte growth factors in a sterile, isotonic solution patterned after amniotic fluid.
Introduction
Feeding intolerance in the neonatal intensive care unit (NICU) can present as distended loops of bowel, emesis, large pre-feeding gastric residuals, diarrhea or gross blood in the stools. 1 These problems can prolong the need for parenteral nutrition and add to the length of the hospitalization. 2 Disuse atrophy of the small bowel mucosa, following several days of enteral fasting, is a factor that might contribute to, or delay recovery from, feeding intolerance among NICU patients. 3 We previously sought to treat small bowel mucosal disuse atrophy by enterally administering a sterile, isotonic, non-caloric, growth factor-containing solution patterned after human amniotic fluid. 4 The experimental solution we devised has the electrolyte composition of amniotic fluid and contains albumin and two enterocyte growth factors present in human amniotic fluid, colostrum and human milk; namely recombinant erythropoietin (rEpo) and recombinant granulocyte-colony stimulating factor (rG-CSF). 5 We previously showed that this experimental amniotic fluid-like solution is stable, 5 and that the growth factors in it are relatively resistant to digestion. 6 We also reported that the cognate receptors for these growth factors are expressed on the luminal surface of fetal intestinal villi. 7, 8 In other studies we showed that when ingested by neonates, these factors are not absorbed into the blood and have no hematopoietic effects. 9, 10 Our previous phase I clinical trials using this solution suggested that it is well tolerated when administered at a dose of 20 ml/kg/ day (2.5 ml/kg every 3 h). 4,11 -14 However, no randomized, controlled trials have previously been carried out testing this solution. The present study was designed as a small, randomized, controlled, masked trial, to obtain preliminary information needed to design a phase III efficacy trial. Specifically, we studied 20 NICU patients who had manifestations of feeding intolerance, randomizing them to either receive the test solution at a dose of 20 ml/kg/day for up to 7 days, or to sham administrations. The researchers and caregivers (except the bedside nurse who actually administered the doses or gave the sham administrations) did not know the randomization group. The outcome measures were the daily enteral calories received during, and for 7 days after, the study treatments.
Methods

Patients
Subjects were eligible for study if they had the diagnosis of feeding intolerance as defined below. Patients were excluded from consideration if they had a congenital surgical condition involving the gastrointestinal tract such as tracheoesophageal fistulae, diaphragmatic hernia, Hirschsprung's disease, bowel atresia, gastroschesis or omphalocele or if they were judged as being too ill to enroll in this study, as defined by a requirement for mechanical ventilation with >50% FIO 2 . Feeding intolerance was defined, for the purpose of the study, as the presence on at least 3 consecutive days of any of the following that thwarted the written enteral feeding plan; increased abdominal girth, emesis, gastric residuals in excess of one feeding, diarrhea, visible blood in the stool not otherwise explained, or abnormally large bowel loops on physical examination or abdominal radiograph. No specific number of cm increase in abdominal girth, or volume of emesis, was required in order to qualify. The criteria for entry into the study was met if increased girth or emesis resulted in the patient being made nothing by mouth (NPO). The Intermountain Healthcare Institutional Review Board approved the protocol and parent's informed consent was obtained.
Study procedures
The hospital pharmacist produced the experimental solution using sterile technique and the parenteral nutrition equipment in the manner previously reported. 5 The solution contained 115 meq/l sodium chloride, 17 meq/l sodium acetate, 4 meq/l potassium chloride, 225 ng/ml rG-CSF (Neupogen, Filgrastim, Amgen Inc., Thousand Oaks, CA, USA) and 4400 mU/ml rEpo (Epoetin alfa, Epogen, Amgen). Human serum albumin (Baxter Health Care Corp, Hyland Division, Glendale, CA, USA) was added to the infusion bag before adding the cytokines (the final concentration of albumin was 0.05%). A patent for this solution is held by the University of Florida (US Patent No. 6956023).
Randomization was performed by the hospital pharmacy department using a random number table. On each day a patient was on study, the pharmacist would sent to the NICU either a full day's dose of test solution (eight syringes, each containing 2.5 ml/ kg) or eight empty syringes. The syringes were covered in pharmacy bags to mask the contents from all except the bedside nurse. The syringes were refrigerated until use. Before administration, a syringe was placed near the patient in the incubator for 10 to 15 min to increase the temperature before it was administered through the oral-gastric or nasal-gastric feeding tube. The nurse either administered the test solution (2.5 ml/k) into the feeding tube (test group) or pretended to administer a solution into the feeding tube (control group). The nurse did not administer 2.5 ml of air into the tube of the control patients, but performed a 'sham' administration. For each of the test solution recipients, the first several administrations consisted of the test solution only. However, once milk feedings were ordered, the test solution was mixed with the milk. The test solution (or sham treatment) was discontinued when the enteral intake reached 80 ml/kg of milk, or after a maximum of 7 days.
Measurement of enteral caloric intake
The volume of milk feeding for each patient was recorded daily, beginning 3 days before the test solution was initiated and ending 7 days after it was discontinued. The estimated volume of any emesis recorded by the bedside nurse, and the estimated volume of any gastric residual that was not returned to the patients, were subtracted from the enteral intake in order to calculate net milk intake per day. For consistency, unfortified human milk was calculated as containing 0.67 cal/ml (20 
Statistical analysis
The purpose of the study was to determine the enteral calories taken during the period the test solution was given, and again during the 7-day period after it had been stopped. Calculations of net enteral calories were expressed as calories/kg body weight/day. Because the outcome of interest (calories/kg/day) was not parametrically distributed, the values were expressed both as median and range. For continuous variables with normal distribution, means and s.d. were used. For comparison of enteral calories taken by the test vs control group and estimates for powering a phase III efficacy trial, independent samples t-tests with unequal variances assumptions were used. A Fisher's Exact test was used to assess differences in categorical variables. The analyses are displayed as one-tailed (consistent with the study hypothesis) and also as two-tailed (given the possibility that the treatment could have resulted in either fewer or more enteral calories), with P<0.05 taken as significant.
Results
During the months of July 2005 to April 2006, the families of 23 eligible NICU patients were contacted to inquire whether they were interested in learning about the feeding tolerance study. Twenty of the 23 families gave written consent for their neonate to participate in the study, and three did not. All 20 where consent was given were enrolled in the study and none were withdrawn from the study after enrolling. No otherwise eligible patients were excluded from the study on the basis that they were judged as being too ill to enroll in the study. The 20 subjects were a heterogeneous group, with birth weights ranging from 403 to 4093 g, and gestational ages ranging from 25 to 39 weeks. The details of the feeding intolerance in each of the 20 subjects are provided in electronic format.
Fourteen of the 20 subjects had feeding intolerance while receiving human milk feedings exclusively. Seven of these 14 were receiving unfortified human milk, whereas seven were receiving human milk fortified to a calculated content of 22 cal/oz (five subjects), or 24 cal/oz (two subjects). Three of the 20 subjects had feeding intolerance while receiving a combination of human milk and infant formula. Two of the 20 had feeding intolerance while exclusively feeding with Enfamil Premature Formula (22 cal/oz, Mead Johnson & Company, Evansville, IN, USA) and one while exclusively feeding with Enfamil (20 cal/oz).
At the time the test solution (or sham) was started, and each day it was given, all 20 patients were receiving parenteral nutrition, including amino acids, electrolytes, trace minerals, vitamins and lipids. None of the study patients had a recognized adverse reaction to the test solution. Specifically, none developed a rash, hypotension, or worsening of respiratory distress or worsening of feeding intolerance during the days the test solution was given.
All decisions regarding when to begin milk feedings, and how rapidly to advance the volumes of those feedings, were made on a daily basis by the attending neonatologist and neonatal nurse practitioner. The test solution was given for as few as 2 days and for as many as 7 days.
Details of the control and test patients demographic findings, enteral calories take during the days before, during and after administering the test solution, are shown in the electronic format (Supplementary Information). Briefly, during the 72 h period preceding administration of the test solution, most of the subjects were receiving no enteral intake, with a range from 0 to 33 cal/k/ day for that 72 h period. There was no difference in number of NPO days in the test vs control group. All 20 were NPO on the day the test/control solutions were begun. During the study period, the test solution recipients trended towards receiving slightly more enteral calories (19.2±16.6 cal/k/day) than the sham recipients (14.2±8.0 cal/k/day). Also, during the 7 days after the cessation of the test administrations, the test solution recipients trended towards receiving more enteral calories (82.9±23.2 cal/k/day) than the sham recipients (65.3±34.1 cal/k/day P ¼ 0.11 one-tailed and P ¼ 0.21 two-tailed). Comparing pretreatment to post-treatment, test solution recipients had a greater increase in enteral calories received than sham recipients (P ¼ 0.05 one tailed and P ¼ 0.10 two tailed). During the 7 days after the cessation of the test/control solution, five of the nine sham recipient had their milk feedings changed to Alimentum (Ross Laboratories, Columbus, OH, USA) or to Alimentum and subsequently to Neocate (Mead Johnson, Evansville, IN, USA). The changes were by physician preference, in an attempt to improve feeding tolerance. The clinicians making these changes were not aware whether the patient had been receiving test or sham treatments. In contrast, only two of the 11 test solution recipients had their milk feedings changed to Alimentum or Neocate; P ¼ 0.10 Fisher Exact).
Discussion
If a fetus fails to swallow amniotic fluid, the small bowel mucosa develops in a disorganized and rudimentary manner. [15] [16] [17] Experiments of Karnak 16 and Trahair 17 showed that the beneficial effect of swallowed amniotic fluid on bowel development comes from the enterocyte growth factors within the fluid, not from the liquid itself. The enterocyte growth factors present in amniotic fluid are also present in colostrum and human milk. 18 However, of these many factors, only rEpo and rG-CSF are currently available in the USA as FDA approved medications. rEpo was first recognized for its antiapoptotic action on erythrocyte progenitors, but it has been subsequently found to have many other important nonerythropoietic functions during human fetal development. These include that of a neuroprotectant and as an antiapoptotic factor involved in development of the fetal gastrointestinal mucosa. 19 rG-CSF was first recognized for its capacity to support the clonal maturation of neutrophils from progenitors, but it subsequently was found to have important developmental and trophic actions on the fetal small bowel mucosa. 20 In the present study, we enrolled 20 patients who had signs of feeding intolerance, and randomized each to either every 3 h feeding of a test solution patterned after human amniotic fluid and containing rEpo and rG-CSF (test group), or a sham administration (control group). A fetus normally swallows 200 to 300 ml of amniotic fluid per kg body weight each day. We reasoned that if the test solution contained 10-fold higher concentrations of growth factors than found in normal amniotic fluid, the volume administered could be reduced 10-fold, to 20 ml/kg/day in order to provide the approximate amount of factors to which the fetal intestine is normally exposed.
In the present study, as with the previous phase I studies of this test solution, 4,11-14 the experimental fluid was well tolerated, with up to 7 days of every 3 h administration. However, the issue of efficacy, in diminishing feeding intolerance, remains undetermined, and can only be addressed using an adequately powered randomized, masked or placebo-controlled design. The present study was performed as a needed step toward the goal of designing such a trial. This was the first study of this solution to employ a randomized, masked design and although only 20 patients were included, the outcomes of interest all showed trends toward improvements among the test solution recipients. Based on the difference of post-treatment enteral calories received between the two study groups, a sample size calculation suggests that 36 neonates per group are needed for an appropriately powered (b ¼ 0.20) study. One limitation of this study is the lack of protocolization of feeding volume increases in neonates after an episode of feeding intolerance. Decisions about the volume of feedings were left entirely to the clinicians on daily rounds, but a better method would have been to devise a set schedule for escalation of volumes, to try to apply to all of the study subjects.
Another limitation of the study is the heterogeneity of the patients. Essentially every study dealing with feeding problems in the NICU grapples with the pleomorphic nature of the problem. Thus, perhaps it is not unexpected that in the present trial the outcomes varied widely, in both treatment and control groups. Specifically, some of the patients in the control and test groups had little or no subsequent feeding problems, whereas others continued to have feeding problems for at least a week or more. We predict that because of the heterogeneous nature of feeding intolerance in the NICU, no single new medication is likely to benefit all cases. In fact, we predict that a solution like the one we tested will be helpful only in cases where the intestinal mucosa has undergone significant atrophic changes, amenable to topical growth factor treatment. Precisely which neonates with feeding problems will benefit from a solution such as the one we tested obviously awaits additional investigation.
